CPA
ARQT icon

Capital Performance Advisors’s Arcutis Biotherapeutics ARQT Stock Holding History

Capital Performance Advisors’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-728
Closed -$6.77K – 355
2024
Q3 		$6.77K Buy
+728
New +$7.18K ﹤0.01% 983

Other funds holding ARQT

Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

Capital Performance Advisors's ARQT Position: Q4 2024 in Review

Capital Performance Advisors sold out of Arcutis Biotherapeutics (ARQT) in Q4 2024, closing a stake of 728 shares — an estimated $6.77K sold.

Capital Performance Advisors first reported a position in ARQT in Q3 2024 and held it in 1 quarter. The position peaked at $6.77K in Q3 2024. 208 funds tracked by Wall St. Rank hold ARQT as of Q4 2024.

  • Capital Performance Advisors reported no remaining Arcutis Biotherapeutics position as of Q4 2024 after selling out during the quarter.
  • Capital Performance Advisors sold 728 Arcutis Biotherapeutics shares in Q4 2024, an estimated $6.77K.
  • Capital Performance Advisors first reported a position in Arcutis Biotherapeutics in Q3 2024 and held it in 1 quarter.
  • Capital Performance Advisors's Arcutis Biotherapeutics position peaked at $6.77K in Q3 2024.
  • 208 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.